Sergio Lira, MD, PhD
img_Sergio Lira
PROFESSOR | Medicine, Clinical Immunology
Research Topics
Autoimmunity, Cancer, Cell Motility, Cellular Immunity, Chemokines, Chemotaxis, Imaging, Immunology, Inflammation, Inflammatory Bowel Disease (IBD), Knockout Mice, Mucosal Immunology, Oncogenes, Organogenesis, Pathology, T Cells, Tolerance, Trafficking, Transgenic Mice, Tumorigenesis, Viruses and Virology
Multi-Disciplinary Training Area
Cancer Biology [CAB], Immunology [IMM]

Specific Clinical/Research Interest: Mucosal Immunology; Microbiota; Cancer; Inflammation; Chemokines; Leukocyte trafficking; Lymphoid Development; Mouse genetics; IL-23 biology

Co-PI: Glaucia Furtado, PhD. Associate Professor

Postdoctoral Fellows: Lili Chen, Zhengziang He, Grace Chen

Visiting Scientist: Valentina Strohmeier (U. Freiburg, Germany)

Summary of Research Studies:
We use genetic approaches in mice to study the function of cytokines and their receptors in mucosal immunology, inflammation and cancer. Recent work in the laboratory focuses:

1) role of microbiome in inflammation in cancer.

2) impact of environmental factors such as diet in inflammation and autoimmunity

3) neonatal inflammation

For more information, please visit the Lira Lab page

  • Engineering mouse mutants using  the CRISPR/Cas technology
  • Single cell transcriptomics
  • Imaging
  • Intestinal organoids

  • Post-doctoral, Roche Institute of Molecular Biology

    MD, U. Federal de Pernambuco

    PhD, University of California

    Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

    Dr. Lira did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

    Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.